DBV's Breakthrough in Peanut Allergy Treatment

about 1 month ago

Chloe Malay

"So, uh DBV, which is another company that I'd heard of before, but um this is a French biotech company and it's up more than 40% this morning. So, massive jump for DBV because of its peanut allergy patch. So um they just published a result of a trial that showed that um their experimental skin patch helped to desensitize children aged 4 to 7 who wore it for a year. So this is a really big breakthrough in the management of peanut allergies. Um and so now it wants to seek US regulatory approval in the first half of 2026. So this is a successful trial that is the culmination of 20 years worth of work for DBV."

The speaker outlines DBV's recent clinical trial success with its peanut allergy patch, noting a significant stock jump of over 40% and highlighting a potential blockbuster opportunity as the company eyes US regulatory approval in the first half of 2026.